Latest Propel Bio Management, LLC Stock Portfolio
Propel Bio Management, LLC Performance:
2025 Q3: 7.49%YTD: 9.29%2024: -19.36%
Performance for 2025 Q3 is 7.49%, and YTD is 9.29%, and 2024 is -19.36%.
About Propel Bio Management, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Propel Bio Management, LLC reported an equity portfolio of $99.9 Millions as of 30 Sep, 2025.
The top stock holdings of Propel Bio Management, LLC are PAGP, ACHV, AKRO. The fund has invested 23.2% of it's portfolio in PLAINS GP HOLDINGS LP-CL and 11.9% of portfolio in ACHIEVE LIFE SCIENCES INC.
The fund managers got completely rid off CAPRICOR THERAPEUTICS INC (CAPR), MAAT PHARMA SACA and ATHIRA PHARMA INC (ATHA) stocks. They significantly reduced their stock positions in PHATHOM PHARMACEUTICALS I (PHAT), ACHIEVE LIFE SCIENCES INC (ACHV) and TSCAN THERAPEUTICS INC (TCRX). Propel Bio Management, LLC opened new stock positions in CELLDEX THERAPEUTICS INC (CLDX), COMPASS PATHWAYS PLC (CMPS) and NEKTAR THERAPEUTICS (NKTR). The fund showed a lot of confidence in some stocks as they added substantially to MILESTONE PHARMACEUTICALS (MIST) and DELCATH SYSTEMS INC (DCTH).
The top stock holdings of Propel Bio Management, LLC are PAGP, ACHV, AKRO. The fund has invested 23.2% of it's portfolio in PLAINS GP HOLDINGS LP-CL and 11.9% of portfolio in ACHIEVE LIFE SCIENCES INC.
The fund managers got completely rid off CAPRICOR THERAPEUTICS INC (CAPR), MAAT PHARMA SACA and ATHIRA PHARMA INC (ATHA) stocks. They significantly reduced their stock positions in PHATHOM PHARMACEUTICALS I (PHAT), ACHIEVE LIFE SCIENCES INC (ACHV) and TSCAN THERAPEUTICS INC (TCRX). Propel Bio Management, LLC opened new stock positions in CELLDEX THERAPEUTICS INC (CLDX), COMPASS PATHWAYS PLC (CMPS) and NEKTAR THERAPEUTICS (NKTR). The fund showed a lot of confidence in some stocks as they added substantially to MILESTONE PHARMACEUTICALS (MIST) and DELCATH SYSTEMS INC (DCTH).
Propel Bio Management, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Propel Bio Management, LLC made a return of 7.49% in the last quarter. In trailing 12 months, it's portfolio return was -35.36%.
New Buys
| Ticker | $ Bought |
|---|---|
| celldex therapeutics inc | 4,009,850 |
| compass pathways plc | 2,922,300 |
| nektar therapeutics | 2,788,100 |
| jasper therapeutics inc | 2,448,560 |
| viridian therapeutics inc | 1,942,200 |
| athira pharma inc | 618,015 |
New stocks bought by Propel Bio Management, LLC
Additions
| Ticker | % Inc. |
|---|---|
| milestone pharmaceuticals | 186 |
| delcath systems inc | 93.99 |
Additions to existing portfolio by Propel Bio Management, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| phathom pharmaceuticals i | -40.09 |
| achieve life sciences inc | -38.46 |
| tscan therapeutics inc | -7.42 |
Propel Bio Management, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| wts - achieve life sci | -13,687 |
| athira pharma inc | -450,823 |
| eiger biopharmaceuticals | -423,000 |
| maat pharma saca | -452,069 |
| chinook therapeutics | -2,500 |
| capricor therapeutics inc | -695,100 |
Propel Bio Management, LLC got rid off the above stocks
Sector Distribution
Propel Bio Management, LLC has about 74.6% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 74.6 |
| Energy | 23.2 |
| Others | 2.2 |
Market Cap. Distribution
Propel Bio Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MICRO-CAP | 37.9 |
| SMALL-CAP | 32.6 |
| MID-CAP | 27.2 |
| UNALLOCATED | 2.2 |
Stocks belong to which Index?
About 23.4% of the stocks held by Propel Bio Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 76.6 |
| RUSSELL 2000 | 23.4 |
Propel Bio Management, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Propel Bio Management, LLC
Propel Bio Management, LLC has 16 stocks in it's portfolio. About 87.1% of the portfolio is in top 10 stocks. PAGP proved to be the most loss making stock for the portfolio. ACHV was the most profitable stock for Propel Bio Management, LLC last quarter.
Last Reported on: 12 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABEO | abeona therapeutics inc | 5.15 | 974,022 | 5,142,840 | unchanged | 0.00 | ||
| ACHV | achieve life sciences inc | 11.94 | 3,786,420 | 11,927,200 | reduced | -38.46 | ||
| ACHV | wts - achieve life sci | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AKRO | akero therapeutics inc | 10.88 | 228,884 | 10,867,400 | unchanged | 0.00 | ||
| APLT | applied therapeutics inc | 6.83 | 11,285,400 | 6,826,550 | unchanged | 0.00 | ||
| ATHA | athira pharma inc | 0.62 | 149,279 | 618,015 | new | |||
| ATHA | athira pharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CAPR | capricor therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CLDX | celldex therapeutics inc | 4.01 | 155,000 | 4,009,850 | new | |||
| CMPS | compass pathways plc | 2.92 | 510,000 | 2,922,300 | new | |||
| DCTH | delcath systems inc | 4.72 | 438,509 | 4,713,970 | added | 93.99 | ||
| EIGR | eiger biopharmaceuticals | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| JSPR | jasper therapeutics inc | 2.45 | 1,028,810 | 2,448,560 | new | |||
| MIST | milestone pharmaceuticals | 10.26 | 5,124,890 | 10,249,800 | added | 186 | ||
| NKTR | nektar therapeutics | 2.79 | 49,000 | 2,788,100 | new | |||
| PAGP | plains gp holdings lp-cl | 23.23 | 1,272,360 | 23,207,800 | unchanged | 0.00 | ||
| PHAT | phathom pharmaceuticals i | 6.52 | 552,927 | 6,507,950 | reduced | -40.09 | ||
| TCRX | tscan therapeutics inc | 3.52 | 1,932,300 | 3,516,790 | reduced | -7.42 | ||
| VRDN | viridian therapeutics inc | 1.94 | 90,000 | 1,942,200 | new | |||
| zevra therapeutics inc | 2.21 | 231,874 | 2,205,120 | unchanged | 0.00 | |||